(Z)-PUGNAc
Based on 4 publication(s) in Google Scholar
(Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form.
For research use only. We do not sell to patients.
- Purity: 99.13%
- CAS No.: 132489-69-1
- Formula: C15H19N3O7
- Molecular Weight:353.33
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) (Z)-PUGNAc
More
Biological Activity
(Z)-PUGNAc amplifies the incorporation of O-GlcNAc on proteins within both HeLa and HEK cell systems[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 132489-69-1
-
Appearance Solid
-
Molecular Weight 353.33
-
Formula C15H19N3O7
-
Color White to light yellow
-
SMILES
O=C(NC1=CC=CC=C1)O/N=C2[C@@H]([C@H]([C@@H]([C@H](O/2)CO)O)O)NC(C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cancer Lett
Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer. [Abstract]2024 May 1:589:216819. PMID: 38522775 -
Clin Sci
Glutamine alleviates immunosuppression in polymicrobial sepsis by augmenting bacterial phagocytosis through sustaining the GFAT-DRP1 dependent mitochondrial calcium dynamics. [Abstract]2025 Oct 22;139(20):1163-1185. PMID: 41082631 -
Clin Transl Med
O-GlcNAcylation promotes malignancy and cisplatin resistance of lung cancer by stabilising NRF2. [Abstract]2024 Oct;14(10):e70037. PMID: 39358921 -
J Anim Sci Biotechnol
HIF1A regulates follicular atresia through O-GlcNAcylation-mediated VEZF1/ET-1/FOXO1/BAX signaling in porcine granulosa cells. [Abstract]2025 Sep 20;16(1):127. PMID: 40973947
Solvent & Solubility
DMSO : 50 mg/mL (141.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.54 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.54 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8302 mL | 14.1511 mL | 28.3022 mL | 70.7554 mL |
| 5 mM | 0.5660 mL | 2.8302 mL | 5.6604 mL | 14.1511 mL | |
| 10 mM | 0.2830 mL | 1.4151 mL | 2.8302 mL | 7.0755 mL | |
| 15 mM | 0.1887 mL | 0.9434 mL | 1.8868 mL | 4.7170 mL | |
| 20 mM | 0.1415 mL | 0.7076 mL | 1.4151 mL | 3.5378 mL | |
| 25 mM | 0.1132 mL | 0.5660 mL | 1.1321 mL | 2.8302 mL | |
| 30 mM | 0.0943 mL | 0.4717 mL | 0.9434 mL | 2.3585 mL | |
| 40 mM | 0.0708 mL | 0.3538 mL | 0.7076 mL | 1.7689 mL | |
| 50 mM | 0.0566 mL | 0.2830 mL | 0.5660 mL | 1.4151 mL | |
| 60 mM | 0.0472 mL | 0.2359 mL | 0.4717 mL | 1.1793 mL | |
| 80 mM | 0.0354 mL | 0.1769 mL | 0.3538 mL | 0.8844 mL | |
| 100 mM | 0.0283 mL | 0.1415 mL | 0.2830 mL | 0.7076 mL |